Key Insights

Highlights

Treatment Research

3 treatments under study, led by Efgartigimod Alfa

Research Leaders

6 sponsors active, led by Autoimmune Neurology Alliance

Related Conditions

Often studied with 15 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
Phase 1/2 (1)
Phase 3 (1)
Phase 4 (1)

Trial Status

Recruiting2
Active Not Recruiting1
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07761026Recruiting

AXIS MG Patient Registry

NCT06106672Phase 1/2Active Not Recruiting

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

NCT06860633Phase 4Recruiting

Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod

NCT03579966Phase 3Terminated

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Showing all 4 trials

Research Network

Common Treatments

  • Efgartigimod Alfa1
  • Amifampridine Phosphate1
  • Cnp1061

Active Sponsors

  • Autoimmune Neurology Alliance1
  • Alira Health1
  • argenx1
  • COUR Pharmaceutical Development Company, Inc.1
  • University of Colorado, Denver1

Top Investigators

Related Conditions

  • Myasthenia Gravis2
  • Myasthenia Gravis Crisis2
  • Myasthenia Gravis Exacerbations2
  • Myasthenia Gravis Musk2
  • Mg1

Activity Timeline